BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18829550)

  • 1. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.
    Yi C; Wilker EW; Yaffe MB; Stemmer-Rachamimov A; Kissil JL
    Cancer Res; 2008 Oct; 68(19):7932-7. PubMed ID: 18829550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
    Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
    J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
    Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
    Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
    Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
    Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.
    Kissil JL; Wilker EW; Johnson KC; Eckman MS; Yaffe MB; Jacks T
    Mol Cell; 2003 Oct; 12(4):841-9. PubMed ID: 14580336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
    Chow HY; Stepanova D; Koch J; Chernoff J
    PLoS One; 2010 Nov; 5(11):e13791. PubMed ID: 21072183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group I Paks as therapeutic targets in NF2-deficient meningioma.
    Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
    Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
    Horiguchi A; Zheng R; Shen R; Nanus DM
    Prostate; 2008 Jun; 68(9):975-84. PubMed ID: 18361411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
    Xiao GH; Gallagher R; Shetler J; Skele K; Altomare DA; Pestell RG; Jhanwar S; Testa JR
    Mol Cell Biol; 2005 Mar; 25(6):2384-94. PubMed ID: 15743831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
    Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
    Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
    Menges CW; Sementino E; Talarchek J; Xu J; Chernoff J; Peterson JR; Testa JR
    Mol Cancer Res; 2012 Sep; 10(9):1178-88. PubMed ID: 22798428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
    Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
    Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways.
    Huynh N; Liu KH; Baldwin GS; He H
    Biochim Biophys Acta; 2010 Sep; 1803(9):1106-13. PubMed ID: 20595063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.
    Demestre M; Messerli SM; Celli N; Shahhossini M; Kluwe L; Mautner V; Maruta H
    Phytother Res; 2009 Feb; 23(2):226-30. PubMed ID: 18726924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
    Lepont P; Stickney JT; Foster LA; Meng JJ; Hennigan RF; Ip W
    Mutat Res; 2008 Jan; 637(1-2):142-51. PubMed ID: 17868749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
    Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
    Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
    Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
    Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.
    Prudnikova TY; Villamar-Cruz O; Rawat SJ; Cai KQ; Chernoff J
    Oncogene; 2016 Apr; 35(17):2178-85. PubMed ID: 26257058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.